182 related articles for article (PubMed ID: 30009185)
1. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
[TBL] [Abstract][Full Text] [Related]
2. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2022 Mar; 38(3):e3500. PubMed ID: 34611978
[TBL] [Abstract][Full Text] [Related]
3. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Front Immunol; 2020; 11():564921. PubMed ID: 33162978
[TBL] [Abstract][Full Text] [Related]
4. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
[TBL] [Abstract][Full Text] [Related]
5. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
Casas R; Dietrich F; Puente-Marin S; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Acta Diabetol; 2022 May; 59(5):687-696. PubMed ID: 35098372
[TBL] [Abstract][Full Text] [Related]
6. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Chéramy M; Skoglund C; Johansson I; Ludvigsson J; Hampe CS; Casas R
Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
[TBL] [Abstract][Full Text] [Related]
7. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
Tavira B; Cheramy M; Axelsson S; Åkerman L; Ludvigsson J; Casas R
Diabetologia; 2017 Jul; 60(7):1276-1283. PubMed ID: 28357504
[TBL] [Abstract][Full Text] [Related]
8. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
[TBL] [Abstract][Full Text] [Related]
9. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
Axelsson S; Chéramy M; Akerman L; Pihl M; Ludvigsson J; Casas R
Diabetes Care; 2013 Nov; 36(11):3418-24. PubMed ID: 23863909
[TBL] [Abstract][Full Text] [Related]
10. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.
Chéramy M; Hampe CS; Ludvigsson J; Casas R
Clin Exp Immunol; 2013 Mar; 171(3):247-54. PubMed ID: 23379430
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes.
Barcenilla H; Pihl M; Wahlberg J; Ludvigsson J; Casas R
Front Immunol; 2021; 12():797172. PubMed ID: 35095874
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
[TBL] [Abstract][Full Text] [Related]
14. A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
Hals IK; Balasuriya C; Casas R; Ludvigsson J; Björklund A; Grill V
Diabetes Obes Metab; 2023 Nov; 25(11):3400-3409. PubMed ID: 37580967
[TBL] [Abstract][Full Text] [Related]
15. Combined Etanercept, GAD-alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes.
Ludvigsson J; Routray I; Vigård T; Hanås R; Rathsman B; Carlsson A; Särnblad S; Albin AK; Arvidsson CG; Samuelsson U; Casas R
Diabetes Metab Res Rev; 2021 Oct; 37(7):e3440. PubMed ID: 33486892
[TBL] [Abstract][Full Text] [Related]
16. GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Arif S; Gomez-Tourino I; Kamra Y; Pujol-Autonell I; Hanton E; Tree T; Melandri D; Hull C; Wherrett DK; Beam C; Roep BO; Lorenc A; Peakman M
Diabetologia; 2020 Jun; 63(6):1186-1198. PubMed ID: 32248243
[TBL] [Abstract][Full Text] [Related]
17. Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
Nowak C; Lind M; Sumnik Z; Pelikanova T; Nattero-Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Hanas R; Hernandez C; Clemente-León M; Gómez-Gila A; Ferrer Lozano M; Sas T; Pruhova S; Dietrich F; Puente-Marin S; Hannelius U; Casas R; Ludvigsson J
J Clin Endocrinol Metab; 2022 Aug; 107(9):2644-2651. PubMed ID: 35665810
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
Pihl M; Akerman L; Axelsson S; Chéramy M; Hjorth M; Mallone R; Ludvigsson J; Casas R
Clin Exp Immunol; 2013 Jun; 172(3):394-402. PubMed ID: 23600827
[TBL] [Abstract][Full Text] [Related]
19. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
[TBL] [Abstract][Full Text] [Related]
20. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
Skoglund C; Chéramy M; Casas R; Ludvigsson J; Hampe CS
Pediatr Diabetes; 2012 May; 13(3):244-50. PubMed ID: 21848927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]